|1.||Sly, William S: 16 articles (01/2016 - 11/2002)|
|2.||Haskins, Mark E: 16 articles (11/2015 - 02/2002)|
|3.||Vlodavsky, Israel: 14 articles (01/2012 - 07/2002)|
|4.||Roffler, Steve R: 13 articles (11/2015 - 11/2002)|
|5.||Vogler, Carole: 13 articles (10/2012 - 11/2002)|
|6.||Ponder, Katherine P: 11 articles (02/2015 - 11/2008)|
|7.||Grubb, Jeffrey H: 11 articles (10/2012 - 11/2002)|
|8.||Sands, Mark S: 10 articles (09/2014 - 07/2002)|
|9.||Ilan, Neta: 10 articles (01/2012 - 05/2004)|
|10.||Sands, M S: 9 articles (04/2007 - 09/2000)|
06/01/2003 - "A comprehensive analysis of AAV1-treated brains from beta-glucuronidase-deficient mice (mucopolysaccharidosis type VII) showed complete reversal of pathology in all areas of the brain for at least 1 year, demonstrating that the combination of this serotype and experimental strategy is therapeutically effective for treating global neurometabolic disorders."
10/16/2012 - "We recently reported that PerT-GUS, a form of β-glucuronidase (GUS) chemically modified to eliminate its uptake and clearance by carbohydrate-dependent receptors, crossed the BBB and cleared neuronal storage in an immunotolerant model of murine mucopolysaccharidosis (MPS) type VII. In this respect, the chemically modified enzyme was superior to native β-glucuronidase. "
09/15/1999 - "To better understand the contribution of specific hematopoietic lineages to the efficacy of BMT, we transplanted beta-glucuronidase-positive mononuclear phagocytes derived from either the peritoneum or from bone marrow in vitro into syngeneic recipients with mucopolysaccharidosis type VII (MPS VII). "
05/01/2000 - "Recombinant adenoviruses expressing human beta-glucuronidase (AxCAhGUS) and CTLA-4Ig (AxCACTLA-4Ig) were generated and therapeutic efficacy was investigated using a murine model of mucopolysaccharidosis type VII (MPSVII). "
09/15/1999 - "Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII."
|2.||Mucopolysaccharidosis VII (Sly Syndrome)
11/16/2001 - "Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII."
03/01/2003 - "In this study, an adenovirus vector expressing human beta-glucuronidase was injected into mice with mucopolysaccharidosis VII within 24 h of birth, and therapeutic efficacy was evaluated. "
10/01/1998 - "The enzymatic activity of beta-glucuronidase in transduced cells were increased above the control level up to 5 wk. Considering that correction of the enzyme deficiency in a small number of hematopoietic cells can be therapeutic for the Sly disease mouse, our data provide encouragement that human trials of gene therapy based on transferring beta-glucuronidase gene to hematopoietic cells may be efficacious."
06/17/2008 - "Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice."
12/01/1993 - "These studies show that recombinant beta-glucuronidase administered to newborn mice reaches the sites of clinically important storage in murine mucopolysaccharidosis VII."
02/15/2012 - "The development of near-IR (NIR) probes for imaging of β-glucuronidase activity would be ideal to allow estimation of reporter expression and for personalized glucuronide prodrug cancer therapy in preclinical studies. "
01/01/1996 - "An experimental study of urinary bladder tumor in rats has demonstrated that their development is suppressed and latency period is increased as a result of a prolonged inhibition of a urine enzyme, beta-glucuronidase by treatment with poglucar."
01/01/1969 - "A histochemical study on the distribution and localization of beta-glucuronidase activity in cerebral tumors."
02/01/1967 - "1. Histochemical study of beta-glucuronidase in solid tumors]."
02/01/1966 - "3. Trial of enzymic diagnosis of cancer by beta-glucuronidase isozyme]."
|4.||Urinary Bladder Neoplasms (Bladder Cancer)
08/01/1984 - "Additionally, 15 bladder cancer patients judged to be disease free for a median time of 5 years did not have elevated levels of urinary beta-glucuronidase when compared to a normal population of 125 individuals. "
11/01/1972 - "Some statistical and experimental studies on the long term administration of -glucuronidase inhibitor (2,5-di-o-acetyl, D-glucaro(1-4)(6-3) dilactone) to patients of bladder tumor]."
04/01/1969 - "[Study of beta-glucuronidase activity in bladder tumors]."
05/01/1966 - "[Studies on urinary beta-glucuronidase in patients with bladder cancer]."
08/01/1984 - "Thus, the high levels of glucuronidase observed in bladder cancer patients are most likely a consequence of disease rather than a cause."
|5.||Wounds and Injuries (Trauma)
02/01/2003 - "To study the wound-responsive expression of CsAAO1 in detail, we examined transgenic tobacco plants harboring a CsAAO1 promoter-beta-glucuronidase fusion gene. "
10/01/1997 - "To study wound-responsive expression of the FAD7 gene in further detail, we analyzed transgenic tobacco plants carrying the -825 Arabidopsis FAD7 promoter-beta-glucuronidase fusion gene. "
03/01/1990 - "Transcriptional fusions between the gene encoding win2 from potato and the reporter gene encoding beta-glucuronidase (GUS) have been used to study the spatial and temporal patterns of wound induced gene activity in transgenic potato and tobacco plants. "
11/01/2010 - "Histochemical observations of Nicotiana benthamiana transformed with 657 bp of the MsPR10.1A promoter fused to the β-glucuronidase (GUS) gene showed that GUS expression was wound-inducible in leaves, which was consistent with MsPR10.1A expression in alfalfa leaves. "
10/01/2006 - "In order to localize cis-regulatory elements involved in the developmental and wound-induced regulation of the At4CL gene family members, At4CL promoter-beta-glucuronidase (GUS) reporter gene fusions were constructed and transferred into Arabidopsis plants. "
|1.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)